{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ZYME","limit":50},"count":50,"signals":[{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ly or unfavorable feedback regarding the scope or design of our clinical trials, or any delay or failure to obtain approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;  inability to obtain sufficient funds required for a clinical trial;  clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;  delays in the testing, val","filed_date":"2026-03-02","accession":"0001937653-26-000015","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":72,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Government Regulation Outside of the United States and Canada In addition to regulations in th","filed_date":"2026-03-02","accession":"0001937653-26-000015","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":56,"context":"f operations. If we elect to progress product candidates internally, our capabilities for later stage drug development and/or commercialization of product candidates, if approved, is limited. We have entered into strategic partnerships with other companies that we believe can provide later stage development and potentially commercialization capabilities, including our collaboration and license agreements with Jazz, BeOne, BMS, GSK","filed_date":"2026-03-02","accession":"0001937653-26-000015","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":70,"context":"meeting of stockholders or until their successors are duly elected and qualified, subject to earlier resignation or removal; | | |  |  |  |  To approve, on an advisory basis, the compensation of our named executive officers; | | |  |  |  |  To ratify the appointment of KPMG LLP, chartered professional accountants (KPMG), as auditors for the Company for the year ending December 31, 2025; and | | |  |  |  |  To transact","filed_date":"2025-11-10","accession":"0001193125-25-274338","full_text":"https://origin.rootz.global/static/filing/0001193125-25-274338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"ims arising in the ordinary course of our business. As of September30, 2025, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2025-11-06","accession":"0001937653-25-000077","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"o claims arising in the ordinary course of our business. As of June30, 2025, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2025-08-07","accession":"0001937653-25-000049","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":37,"context":"claims arising in the ordinary course of our business. As of March31, 2025, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2025-05-08","accession":"0001937653-25-000027","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"rams, including some that may be for the same indication as our product candidates; any delay or failure to obtain approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; inability to obtain sufficient funds required for a clinical trial; inability to recruit clinical operations personnel and other personnel with later-stage development experience; clin","filed_date":"2025-03-05","accession":"0001937653-25-000014","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":80,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Government Regulation Outside of the United States and Canada In addition to regulations in th","filed_date":"2025-03-05","accession":"0001937653-25-000014","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":51,"context":"hips are not successful, our business could be adversely affected. We have limited capabilities for drug development and commercialization of our product candidates, if approved. Accordingly, we have entered into strategic partnerships with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Jazz, BeiGene, BMS, GSK, Daiichi Sankyo, Janssen and Merck. These relation","filed_date":"2025-03-05","accession":"0001937653-25-000014","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":45,"context":"ims arising in the ordinary course of our business. As of September30, 2024, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2024-10-31","accession":"0001937653-24-000050","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":84,"context":"meeting of stockholders or until their successors are duly elected and qualified, subject to earlier resignation or removal; | | |  |  |  |  To approve, on an advisory basis, the compensation of our named executive officers; | | |  |  |  |  To ratify the appointment of KPMG LLP, chartered professional accountants (KPMG), as auditors for the Company for the year ending December 31, 2024; and | | |  |  |  |  To transact","filed_date":"2024-10-29","accession":"0001193125-24-246527","full_text":"https://origin.rootz.global/static/filing/0001193125-24-246527.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to so qualify or to be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below).  5  (f) Capitalization. All the outstanding capital stock of the Company and each of its subsidiaries has been duly and validly authorized and issued and is fully paid and non-ass","filed_date":"2024-08-02","accession":"0001193125-24-192058","full_text":"https://origin.rootz.global/static/filing/0001193125-24-192058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":45,"context":"o claims arising in the ordinary course of our business. As of June30, 2024, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2024-08-01","accession":"0001937653-24-000041","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"claims arising in the ordinary course of our business. As of March31, 2024, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2024-05-02","accession":"0001937653-24-000028","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"rams, including some that may be for the same indication as our product candidates; any delay or failure to obtain approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; inability to obtain sufficient funds required for a clinical trial; inability to recruit clinical operations personnel and other personnel with later-stage development experience; clin","filed_date":"2024-03-06","accession":"0001937653-24-000019","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":84,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Government Regulation Outside of the United States and Canada In addition to regulations in th","filed_date":"2024-03-06","accession":"0001937653-24-000019","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":57,"context":"hips are not successful, our business could be adversely affected. We have limited capabilities for drug development and commercialization of our product candidates, if approved. Accordingly, we have entered into strategic partnerships with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Jazz, BeiGene, BMS, GSK, Daiichi Sankyo, Janssen, Iconic and Merck. These","filed_date":"2024-03-06","accession":"0001937653-24-000019","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"ims arising in the ordinary course of our business. As of September30, 2023, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2023-11-07","accession":"0001937653-23-000037","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":71,"context":"meeting of stockholders or until their successors are duly elected and qualified, subject to earlier resignation or removal; | | |  |  |  |  To approve, on an advisory basis, the compensation of our named executive officers; | | |  |  |  |  To ratify the appointment of KPMG LLP, chartered professional accountants (KPMG), as auditors for the Company for the year ending December 31, 2023; and | | |  |  |  |  To transact","filed_date":"2023-10-26","accession":"0001193125-23-264097","full_text":"https://origin.rootz.global/static/filing/0001193125-23-264097.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":43,"context":"o claims arising in the ordinary course of our business. As of June30, 2023, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2023-08-10","accession":"0001937653-23-000028","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ase two dose (RP2D) of 2.5 mg/kg dosed every three weeks. Before the end of 2023, we expect to present additional data from our Phase 1 clinical trial that further supports this RP2D and commence enrollment in multiple Phase 2 studies.  We are also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeu","filed_date":"2023-05-08","accession":"0001937653-23-000018","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"claims arising in the ordinary course of our business. As of March31, 2023, we are not a party to any legal proceedings that, in the opinion of our management, would reasonably be expected to have a material adverse effect on our business, financial condition, operating results or cash flows if determined adversely to us. Regardless of the outcome, litigation can have an adverse impact on us because of defense and sett","filed_date":"2023-05-08","accession":"0001937653-23-000018","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":48,"context":", a NaPi2b targeted ADC with a TOPO1i-based payload, as well as additional preclinical product candidates currently in development.  Licensing and Collaboration Agreements  In April 2022, Atreca Inc. announced a licensing agreement with Zymeworks to utilize our ZymeLink technology to develop novel ADCs. We received an undisclosed upfront payment in association with this licensing agreement in conjunction with future option exer","filed_date":"2023-04-28","accession":"0001193125-23-126974","full_text":"https://origin.rootz.global/static/filing/0001193125-23-126974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ase two dose (RP2D) of 2.5 mg/kg dosed every three weeks. Before the end of 2023, we expect to present additional data from our Phase 1 clinical trial that further supports this RP2D and commence enrollment in multiple Phase 2 studies.  We are also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeu","filed_date":"2023-03-07","accession":"0001937653-23-000011","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":44,"context":"tances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. Government Regulation Outside of the United States and Canada In addition to regulations in th","filed_date":"2023-03-07","accession":"0001937653-23-000011","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"w:  46  [Table of Contents](#toc) |  |  |  |  |  | | |  2021 Corporate GoalCategory |  |  Key Elements of Goal |  |  TargetWeight ofGoal | | |  |  |  | | |  Clinical |  |  ZW25-203: completion of enrollment of targeted number of efficacy evaluable patients by December 31, 2021 |  |  20% | | |  |  ZW25-301: completion of enrollment of targeted number of efficacy evaluable patients by December 31, 2021","filed_date":"2022-11-25","accession":"0001193125-22-292281","full_text":"https://origin.rootz.global/static/filing/0001193125-22-292281.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":67,"context":"nic.  In December 2021, BeiGene dosed the first patient in South Korea in the pivotal HERIZON-GEA-01 study. We received a payment of $8.0 million in relation to this milestone.  In April 2022, Atreca announced a licensing agreement with us to utilize our ZymeLink technology to develop novel ADCs. We recognized a $5.0 million research license fee payment in association with this licensing agreement in conjunction with future opt","filed_date":"2022-11-25","accession":"0001193125-22-292281","full_text":"https://origin.rootz.global/static/filing/0001193125-22-292281.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to so qualify or to be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below).  (f) Capitalization. All the outstanding capital stock of the Company and each of its subsidiaries has been duly and validly authorized and issued and is fully paid and non-assess","filed_date":"2022-11-09","accession":"0001193125-22-281294","full_text":"https://origin.rootz.global/static/filing/0001193125-22-281294.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"shutdowns or other business interruptions could result in material and negative effects to our ability to conduct our business in the manner and on the timelines currently planned, which could have a material adverse impact on our business, results of operations, and financial condition. The COVID-19 pandemic continues to rapidly evolve, and we will continue to monitor the effects of COVID-19 on our business and review","filed_date":"2022-11-08","accession":"0001937653-22-000009","full_text":"https://origin.rootz.global/static/filing/0001937653-22-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":42,"context":"is in good standing under the laws of each jurisdiction which requires such qualification, except where the failure to so qualify or to be in good standing would not reasonably be expected to have a Material Adverse Effect (as defined below).  (f) Capitalization. All the outstanding capital stock of the Company and each of its subsidiaries has been duly and validly authorized and issued and is fully paid and non-assess","filed_date":"2022-10-21","accession":"0001193125-22-266760","full_text":"https://origin.rootz.global/static/filing/0001193125-22-266760.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"modifying or waiving provisions of any contracts, relating to the royalties receivable under the Covered Agreements that would undermine the Royalty Interest or reasonably be expected to result in a material adverse effect, (ii) taking actions that would, or would give the right to an applicable commercial partner to, terminate a Covered Agreement or certain material in-license agreements covering Ziihera, or amending,","filed_date":"2026-08-06","accession":"0001937653-26-000047","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":98,"match_count":6,"context":"elect to progress product candidates internally, our capabilities for 50Table of Contents later stage drug development and/or commercialization of product candidates, if approved, is limited. We have entered into strategic partnerships with other companies that we believe can provide later stage development and potentially commercialization capabilities, including our collaboration and license agreements with Jazz, BeOne, GSK, Dai","filed_date":"2026-08-06","accession":"0001937653-26-000047","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"mended phase two dose (RP2D) of 2.5 mg/kg dosed every three weeks. Before the end of 2023, we expect to present additional data from our Phase 1 clinical trial that further supports this RP2D and enrollment in a Phase 2 study.  We are also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas","filed_date":"2023-08-10","accession":"0001937653-23-000028","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ating zanidatamab for the first-line treatment of HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinomas (GEA). The pivotal HERIZON-GEA-01 trial is ongoing and enrollment remains on track. Based on a blinded assessment of progression events, Jazz estimates top-line progression-free survival (PFS) data will be available in the second quarter of 2025. Jazz continues","filed_date":"2024-08-01","accession":"0001937653-24-000041","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"in at the recommended phase two dose (RP2D) of 2.5 mg/kg dosed every three weeks. In October 2023, we presented additional data from our Phase 1 clinical trial that further supports this RP2D and enrollment in a Phase 2 study. We are currently pursuing the initiation of a Phase 2 study of zanidatamab zovodotin in combination with a PD-1 inhibitor in subjects with locally advanced (unresectable) or me","filed_date":"2023-11-07","accession":"0001937653-23-000037","full_text":"https://origin.rootz.global/static/filing/0001937653-23-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"lemented by support from external contract research organizations (CROs) to complement the temporarily reduced capacity at our lab facilities. Certain clinical trial activities, including patient enrollment and site activations, were delayed or otherwise impacted by COVID-19. To date, COVID-19 has not had a material impact on our financial condition, liquidity or longer-term strategic development and","filed_date":"2022-11-08","accession":"0001937653-22-000009","full_text":"https://origin.rootz.global/static/filing/0001937653-22-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":87,"match_count":9,"context":"currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred. 14. Restructuring In January 2022, the Company started implementing a restructuring program (the Restructuring) as part of its renewed focus on achieving its key strategic priorities and to help create a more cost-efficient organization in order to execute on its strategic priorities. In co","filed_date":"2022-11-08","accession":"0001937653-22-000009","full_text":"https://origin.rootz.global/static/filing/0001937653-22-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"|  |  |  |  Our partner, Jazz Pharmaceuticals, gained alignment with FDA on the confirmatory trial evaluating zanidatamab in first-line metastatic BTC patients. | | |  |  |  |  Continued patient enrollment in the HERIZON-GEA-01 (NCT05152147) pivotal clinical study for zanidatamab in first-line HER2-positive GEA (Jazz estimates top-line progression-free survival data will be available in the second q","filed_date":"2024-10-29","accession":"0001193125-24-246527","full_text":"https://origin.rootz.global/static/filing/0001193125-24-246527.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ent | | |  Clinical and CMC |  |  ZanidatamabBTC: Fully recruit the HERIZON-BTC-01 pivotal clinical study by mid-2022, and stretch goals related to database lock and topline data  ZanidatamabGEA: Enrollment of 250 patients in HERIZON-GEA-01 pivotal clinical study by year end, and stretch goals related to enrollment targets and submission of supportive clinical data |  |  40% for base goals; an additi","filed_date":"2023-10-26","accession":"0001193125-23-264097","full_text":"https://origin.rootz.global/static/filing/0001193125-23-264097.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation, tariffs and trade policies. In addition, the probability of success for each product candidate will depend on numerous factors, including","filed_date":"2025-11-06","accession":"0001937653-25-000077","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation, tariffs and trade policies. In addition, the probability of success for each product candidate will depend on numerous factors, including","filed_date":"2025-08-07","accession":"0001937653-25-000049","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000049.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing c","filed_date":"2024-10-31","accession":"0001937653-24-000050","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000050.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing c","filed_date":"2024-05-02","accession":"0001937653-24-000028","full_text":"https://origin.rootz.global/static/filing/0001937653-24-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"votal clinical study by mid-2022, and stretch goals related to database lock and topline data |  |  40% for base goals; an additional 30% for stretch goals |  |  56.35% | | |  |  Zanidatamab GEA: Enrollment of 250 patients in HERIZON-GEA-01 pivotal clinical study by year end, and stretch goals related to enrollment targets and submission of supportive clinical data | | |  |  Zanidatamab Other: Comple","filed_date":"2023-04-28","accession":"0001193125-23-126974","full_text":"https://origin.rootz.global/static/filing/0001193125-23-126974.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"non-human primates of 60 mg/kg, which presents a compelling profile and enables the expectation of potentially achieving an efficacious dose level in the Phase 1 clinical trial. We have completed enrollment for the ongoing global Phase 1, open-label, multicenter study of ZW191, registered under NCT06555744 on clinicaltrials.gov. The study aimed to enroll approximately 145 participants with advanced s","filed_date":"2026-08-06","accession":"0001937653-26-000047","full_text":"https://origin.rootz.global/static/filing/0001937653-26-000047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":70,"match_count":5,"context":"2024, were highlighted along with other preclinical product candidates and platform technologies at the ER&D update on October 20, 2022. Licensing and Collaboration Agreements: In April 2022, Atreca announced a licensing agreement with us to utilize our ZymeLink technology to develop novel ADCs. We recognized a $5.0 million research license fee payment in association with this licensing agreement in conjunction with future opt","filed_date":"2022-11-08","accession":"0001937653-22-000009","full_text":"https://origin.rootz.global/static/filing/0001937653-22-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"nical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation, tariffs and trade policies. In addition, the probability of success for each product candidate will depend on numerous factors, including","filed_date":"2025-05-08","accession":"0001937653-25-000027","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000027.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"toc) |  | |  2024 Corporate Goal Category |  |  Key Elements of Goal |  |  Target Weight of Goal |  |  AssessedAchievement |  | | |  |  Advance clinical trials of zanidatamab, including: complete enrollment of HERIZON-GEA-01; first patient enrolled in Phase 3 confirmatory trial for zanidatamab in first-line BTC; no material disruption to clinical drug supply of zanidatamab for any studies being condu","filed_date":"2025-11-10","accession":"0001193125-25-274338","full_text":"https://origin.rootz.global/static/filing/0001193125-25-274338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ZYME","company":"Zymeworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":43,"match_count":1,"context":"ships are not successful, our business could be adversely affected.We have limited capabilities for drug development and commercialization of our product candidates, if approved. Accordingly, we have entered into strategic partnerships with other companies that we believe can provide such capabilities, including our collaboration and license agreements with Jazz, BeOne, BMS, GSK, Daiichi Sankyo, J&J and Merck. These relationships","filed_date":"2025-11-06","accession":"0001937653-25-000077","full_text":"https://origin.rootz.global/static/filing/0001937653-25-000077.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"031d9d85891bcbb5c77f03dc422d669283468cf2968a8c5069b0129604f346aa","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"125200796d595299ea28ae3c07d53ae881373c91bd039c8c257fdbe5df803ab6","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":478,"hourly_limit":500,"remaining":22,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}